News | September 16, 2024
Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana
Total investment incurred for setting up the new R&D Rs 250 crore
Total investment incurred for setting up the new R&D Rs 250 crore
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Subscribe To Our Newsletter & Stay Updated
